| ADA kicks off GLP-1 succession saga
|
(Amylin Pharmaceuticals)
|
10-Jun-2008 |
| After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight
|
(Amylin Pharmaceuticals)
|
09-Jun-2008 |
| After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight
|
(Eli Lilly)
|
09-Jun-2008 |
| ADA - DPP-IVs and GLP-1s steal the show
|
(Merck & Co)
|
09-Jun-2008 |
| Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin
|
(Amylin Pharmaceuticals)
|
09-Jun-2008 |
| After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight
|
(Alkermes)
|
09-Jun-2008 |
| Monotherapy BYETTA® (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
|
(Eli Lilly)
|
07-Jun-2008 |
| Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
|
(Eli Lilly)
|
07-Jun-2008 |
| Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
|
(Alkermes)
|
07-Jun-2008 |
| Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
|
(Amylin Pharmaceuticals)
|
07-Jun-2008 |
| Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
|
(Amylin Pharmaceuticals)
|
07-Jun-2008 |
| Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
|
(Amylin Pharmaceuticals)
|
05-May-2008 |
| SYMLIN Pen-Injector Devices Now Available
|
(Amylin Pharmaceuticals)
|
07-Jan-2008 |
| Monotherapy BYETTA® Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes
|
(Eli Lilly)
|
06-Dec-2007 |
| Monotherapy BYETTA(R) Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes
|
(Amylin Pharmaceuticals)
|
06-Dec-2007 |
| Amylin Pharmaceuticals to Present at Research & Development Day
|
(Amylin Pharmaceuticals)
|
21-Nov-2007 |
| Pramlintide and Leptin Combination Treatment Demonstrates 12.7 Percent Weight Loss in 24-Week Clinical Obesity Study
|
(Amylin Pharmaceuticals)
|
15-Nov-2007 |
| Novo Nordisk should play Liraglutide time advantage
|
(Novo Nordisk)
|
01-Nov-2007 |
| Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study
|
(Eli Lilly)
|
31-Oct-2007 |
| FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use
|
(Amylin Pharmaceuticals)
|
01-Oct-2007 |
| BYETTA® Study Showed Sustained Blood Glucose Control Over Three Years in People with Type 2 Diabetes
|
(Eli Lilly)
|
25-Jun-2007 |
| BYETTA® Study Showed Comparable Blood Glucose Control to Insulin
|
(Eli Lilly)
|
24-Jun-2007 |
| BYETTA® Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
|
(Eli Lilly)
|
23-Jun-2007 |
| SYMLIN(R) Used in Conjunction with Basal Insulin in Patients with Type 2 Diabetes
|
(Amylin Pharmaceuticals)
|
23-Jun-2007 |
| Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007
|
(Amylin Pharmaceuticals)
|
19-Jun-2007 |